27098 Federal Register / Vol. 61, No. 105 / Thursday, May 30, 1996 / Notices

201, subparts A through E (19 CFR part

201), and part 207, subparts A and C (19

CFR part 207).

EFFECTIVE DATE: May 10, 1996.

FOR FURTHER INFORMATION CONTACT:

Debra Baker (202–205–3180), Office of

Investigations, U.S. International Trade

Commission, 500 E Street SW.,

Washington, DC 20436. Hearingimpaired persons can obtain

information on this matter by contacting

the Commission’s TDD terminal on 202–

205–1810. Persons with mobility

impairments who will need special

assistance in gaining access to the

Commission should contact the Office

of the Secretary at 202–205–2000.

General information concerning the

Commission may also be obtained by

accessing its internet server (http://

www.usitc.gov or ftp://ftp.usitc.gov).

SUPPLEMENTARY INFORMATION:

Background

This investigation is being instituted

as a result of an affirmative preliminary

determination by the Department of

Commerce that imports of foam

extruded PVC and polystyrene framing

stock from the United Kingdom are

being sold in the United States at less

than fair value within the meaning of

section 733 of the Act (19 U.S.C. 1673b).

The investigation was requested in a

petition filed on September 8, 1995, by

Marley Mouldings, Inc., Marion, VA.

Participation in the Investigation and

Public Service List

Persons wishing to participate in the

investigation as parties must file an

entry of appearance with the Secretary

to the Commission, as provided in

section 201.11 of the Commission’s

rules, not later than twenty-one (21)

days after publication of this notice in

the Federal Register. The Secretary will

prepare a public service list containing

the names and addresses of all persons,

or their representatives, who are parties

to this investigation upon the expiration

of the period for filing entries of

appearance.

Limited Disclosure of Business

Proprietary Information (BPI) Under an

Administrative Protective Order (APO)

and BPI Service List

Pursuant to section 207.7(a) of the

Commission’s rules, the Secretary will

make BPI gathered in this final

investigation available to authorized

applicants under the APO issued in the

investigation, provided that the

application is made not later than

twenty-one (21) days after the

publication of this notice in the Federal

Register. A separate service list will be

maintained by the Secretary for those

parties authorized to receive BPI under

the APO.

Staff Report

The prehearing staff report in this

investigation will be placed in the

nonpublic record on September 12,

1996, and a public version will be

issued thereafter, pursuant to section

207.21 of the Commission’s rules.

Hearing

The Commission will hold a hearing

in connection with this investigation

beginning at 9:30 a.m. on September 27,

1996, at the U.S. International Trade

Commission Building. Requests to

appear at the hearing should be filed in

writing with the Secretary to the

Commission on or before September 20,

1996. A nonparty who has testimony

that may aid the Commission’s

deliberations may request permission to

present a short statement at the hearing.

All parties and nonparties desiring to

appear at the hearing and make oral

presentations should attend a

prehearing conference to be held at 9:30

a.m. on September 24, 1996, at the U.S.

International Trade Commission

Building. Oral testimony and written

materials to be submitted at the public

hearing are governed by sections

201.6(b)(2), 201.13(f), and 207.23(b) of

the Commission’s rules. Parties are

strongly encouraged to submit as early

in the investigation as possible any

requests to present a portion of their

hearing testimony in camera.

Written Submissions

Each party is encouraged to submit a

prehearing brief to the Commission.

Prehearing briefs must conform with the

provisions of section 207.22 of the

Commission’s rules; the deadline for

filing is September 19, 1996. Parties

may also file written testimony in

connection with their presentation at

the hearing, as provided in section

207.23(b) of the Commission’s rules,

and posthearing briefs, which must

conform with the provisions of section

207.24 of the Commission’s rules. The

deadline for filing posthearing briefs is

October 3, 1996; witness testimony must

be filed no later than three days before

the hearing. In addition, any person

who has not entered an appearance as

a party to the investigation may submit

a written statement of information

pertinent to the subject of the

investigation on or before October 3,

1996. On October 24, 1996, the

Commission will make available to

parties all information on which they

have not had an opportunity to

comment. Parties may submit final

comments on this information on or

before October 29, 1996, but such final

comments must not contain new factual

information, or comment on information

disclosed prior to the filing of

posthearing briefs, and must otherwise

comply with section 207.29 of the

Commission’s rules. All written

submissions must conform with the

provisions of section 201.8 of the

Commission’s rules; any submissions

that contain BPI must also conform with

the requirements of sections 201.6,

207.3, and 207.7 of the Commission’s

rules.

In accordance with sections 201.16(c)

and 207.3 of the rules, each document

filed by a party to the investigation must

be served on all other parties to the

investigation (as identified by either the

public or BPI service list), and a

certificate of service must be timely

filed. The Secretary will not accept a

document for filing without a certificate

of service.

Authority: This investigation is being

conducted under authority of the Tariff Act

of 1930, title VII. This notice is published

pursuant to section 207.20 of the

Commission’s rules.

Issued: May 24, 1996.

By order of the Commission.

Donna R. Koehnke,

Secretary.

[FR Doc. 96–13571 Filed 5–29–96; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.43(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on April 25,

1996, Lonza Riverside, 900 River Road,

Conchohocken, Pennsylvania 19428,

made application to the Drug

Enforcement Administration (DEA) for

registration as a bulk manufacturer of

the basic classes of controlled

substances listed below:

Drug Schedule

4-Methoxyamphetamine (7411) I

Amphetamine (1100) ................ II

Phenylacetone (8501) ............... II

The firm plans to manufacture the

listed controlled substances in bulk for

distribution to its customers.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the above application.
Federal Register / Vol. 61, No. 105 / Thursday, May 30, 1996 / Notices 27099

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistance Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 29,

1996.

Dated: May 22, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 96–13559 Filed 5–29–96; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.43(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on April 22,

1996, Research Triangle Institute,

Kenneth H. Davis, Jr., Hermann

Building, East Institute Drive, P.O. Box

12194, Research Triangle Park, North

Carolina 27709, made application to the

Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Marihuana (7360) ..................... I

Cocaine (9041) ......................... II

The Institute will manufacture

marihuana cigarettes for the National

Institute on Drug Abuse (NIDA) and the

cocaine will be used for reference

standards, human and animal research,

as dictated by NIDA.

Any other such applicant and any

person who is presently registered with

DEA to manufacture such substances

may file comments or objections to the

issuance of the above application.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 29,

1996.

Dated: May 21, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 96–13560 Filed 5–29–96; 8:45 am]

BILLING CODE 4410–09–M

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to Section 1301.43(a) of Title

21 of the Code of Federal Regulations

(CFR), this is notice that on April 14,

1996, Roche Diagnostic Systems, Inc.,

1080 U.S. Highway 202, Somerville,

New Jersey 08876–3771, made

application to the Drug Enforcement

Administration (DEA) for registration as

a bulk manufacturer of the basic classes

of controlled substances listed below:

Drug Schedule

Lysergic acid diethylamide

(7315) .................................... I

Tetrahydrocannabinols (7370) I

The firms plans to manufacture small

quantities of the listed controlled

substances for incorporation in drug of

abuse detection kits.

Any other such applicant and any

person who is presently registered with

DEA to manufacturer such substances

may file comments or objections to the

issuance of the above application.

Any such comments or objections

may be addressed, in quintuplicate, to

the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than July 29,

1996.

Dated: May 21, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 96–13561 Filed 5–29–96; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1311.42 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on March 29, 1996, Roche

Diagnostic Systems, Inc., 1080 U.S.

Highway 202, Somerville, New Jersey

08876, made application to the Drug

Enforcement Administration to be

registered as an importer of

tetrahydrocannabinols (7370) a basic

class of controlled substance listed in

Schedule I.

The tetrahydrocannabinols will be

utilized exclusively for non-human

consumption in drug of abuse detection

kits.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.54 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, D.C.

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than July 1, 1996.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1311.42 (b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import a basic class of

any controlled substance in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1311.42 (a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: May 22, 1996.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 96–13562 Filed 5–29–96; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of